Abstract:Purpose/Objective(s) programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1 inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainty about the timing, fraction dose and total dose for PD-1 inhibitors combination with radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new pattern for R/M NPC. Materials/Methods We prospectively enrolled 42 R/M NPC patients from August 2018 to May 2021 in out institution. All the patients received concurrent PD-1 inhibitor combination with chemoradiation, and followed with maintenance of PD-1 inhibitors, and we analyzed PD-L1 expression by 22C3 kit. Objective response rate (ORR) and disease control rate (DCR) were calculated by irRECIST 1.1. CTCAE-5.0 was used to evaluate the toxicity and Kaplan-Meier method was used to analyze survival rate. Results The median age was 48 years old (range 25-81), the median follow up time was 16.5 months (range 2-62). Nine patients had recurrent disease, 33 patients had metastatic disease, and 3 patients had both recurrence and metastasis disease. The median numbers of metastatic sites were 3 (range 1-7), and the most common metastatic sites were lung and liver. All the recurrent and measurable metastatic lesions were treated with radiotherapy. 9 recurrent patients received a median radiation dose of 60Gy. The measurable metastatic lesions received a median radiation dose of 54Gy. The median cycles of cisplatin-based chemotherapy were 5. Median time of PD-1 inhibitor was 9.5 months. At 3 months after the completion of chemoradiation, ORR and DCR were 90.5% and 100% respectively. The median PFS was 18 months, with 6 and 12 months PFS rates were 90.2% and 70.7%. 1 and 2-years OS rates were 94.6% and 86.2%, and the median OS had not reached. For the PD-L1 expression, 24 patients were positive, 18 were negative. The median PFS was 20.7 and 16.5 months for positive and negative group, respectively (p=0.01). Most common G3-4 toxicities were leucopenia (45.2%), anemia (38.1%), anorexia (7.1%), and fatigue (7.1%). There was no G3-4 toxicity for pneumonia, and no G5 toxicity was observed. Conclusion This new treatment pattern of concurrent PD-1 inhibitors combination with chemoradiation shows a promising efficacy and tolerable toxicity for R/M NPC. The patients with positive PD-L1 expression had better survival outcome than negative group. Keywords: PD-1 inhibitors, concurrent, recurrent, metastatic, nasopharyngeal carcinoma, chemoradiation

Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents

Survival Benefit Of Adding Chemotherapy To Intensity Modulated Radiation In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy

Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes for Stage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.

Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients with Newly Diagnosed Metastatic Nasopharyngeal Cancer

Chemotherapy plus radiotherapy makes curability a possibility in nasopharyngeal carcinoma patients with distant metastasis at diagnosis

Preliminary Analysis of Concurrent Programmed Cell Death-1 Inhibitor Combination with Chemoradiation for Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: A Phase II Study

Long-term Efficacy of Induction Chemotherapy Plus Concurrent Radiochemotherapy on Advanced Nasopharyngeal Carcinoma

The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.

Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.

Concurrent Chemoradiotherapy with Additional Chemotherapy for Nasopharyngeal Carcinoma: A Pooled Analysis of Propensity Score‐matching Studies

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

IMRT Combined with Concurrent Chemotherapy Plus Adjuvant Chemotherapy Versus IMRT Combined with Concurrent Chemotherapy Alone in Patients with Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy with or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: an Update.